ClinicalTrials.gg
RecruitingNCT06780137Updated Oct 6, 2026

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

A Phase 1/2 interventional study of Gocatamig and Ifinatamab Deruxtecan (I-DXd) in Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 48 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc — 3 open to participants now, 8 under way, 3 of them phase 3. Small Cell Lung Carcinoma · Merck & Co., Inc.

Planned enrollment
6th of 12
327 · median 280
Started
2025
the only one that year
Phase 1/2
4 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 1/2, and was the 10th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

3 of the 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment.

The goals of this study are to learn:

  • If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated
  • If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away
Read the detailed description

This study will consist of two parts. Part 1 will assess the safety, tolerability, and efficacy of gocatamig and I-DXd at doses determined in study MK-6070-001 (NCT: NCT04471727). Part 2 will assess the safety and tolerability of gocatamig in participants in Japan and China. Part 3 will assess the safety, tolerability, and efficacy of gocatamig with durvalumab.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed SCLC that is extensive stage (defined as Stage IV (T any, N any, M1a/b/c) following at least 1 that included platinum-based chemotherapy
  • Must be able to provide sample or fresh biopsy tissue sample
  • (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)

Exclusion criteria

Exclusion Criteria:

  • Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedure
  • Any history of interstitial lung disease (ILD)/pneumonitis irrespective of use except for a history of radiation pneumonitis that did not require steroids
  • Current history of ILD or clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Active or history of immune deficiency with the exception of -infected participants with well controlled HIV on ART
  • History within 6 months before the first dose of study intervention of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF) ( > class II), and/or uncontrolled cardiac arrhythmia
  • History of arterial thrombosis (eg, stroke or ) within 6 months before the first dose of study intervention
  • Active clinically significant infection requiring systemic therapy
  • History of allogeneic tissue/solid organ transplant
  • History of
  • Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of chronic therapy within 7 days prior to the first dose of study intervention
  • Known additional that is progressing or has required active treatment within the past 3 years
  • Untreated or symptomatic
  • Active viral hepatitis, defined as hepatitis A (hepatitis A virus immunoglobulin M [IgM] positive in the setting of associated signs/symptoms), (hepatitis B virus surface antigen [HbsAg] positive and/or detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA]), or (hepatitis C virus [HCV] antibody positive and detectable HCV ribonucleic acid). Participants with HBV with undetectable viral load after treatment are eligible. Participants with HCV with undetectable virus after treatment are eligible.
  • Part 1 only: Radiation therapy to the lung >30 Gy within 6 months before the start of study intervention
  • Part 1 only: Abdominal radiation within 4 weeks before start of study intervention
  • Part 1 only: Anticancer hormonal treatment (except luteinizing hormone-releasing hormone [LHRH]) within 2 weeks before start of study intervention
  • Part 1 only: Systemic anticancer therapy (except antibody-based anticancer therapy) or agents within 3 weeks or 5 half-lives, whichever is longer
  • Part 1 only: Antibody-based cancer therapy within 3 weeks before start of study intervention
  • Part 1 only: Chloroquine/hydroxychloroquine within 2 weeks before start of study intervention
  • Part 1 only: Clinically significant corneal disease
  • Part 1 only: Has other uncontrolled or significant protocol-specified cardiovascular disease
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
327 participants (estimated)

Study arms

  • Experimental
    Part 1 Arm 1: Gocatamig and I-DXd

    Participants will receive gocatamig and I-DXd at a determined dose until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig · Biological: Ifinatamab Deruxtecan (I-DXd)

  • Experimental
    Part 1 Arm 2: Gocatamig and I-DXd

    Participants will receive gocatamig and I-DXd at a determined dose until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig · Biological: Ifinatamab Deruxtecan (I-DXd)

  • Experimental
    Part 1 Arm 3a: I-DXd Monotherapy

    Participants will receive I-DXd until documented disease progression or discontinuation criteria are met.

    Biological: Ifinatamab Deruxtecan (I-DXd)

  • Experimental
    Part 1 Arm 3b: Gocatamig and I-DXd

    Participants will receive gocatamig and I-DXd at a determined dose until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig · Biological: Ifinatamab Deruxtecan (I-DXd)

  • Experimental
    Part 2 Arm 4: Gocatamig Monotherapy in Japan

    Participants in Japan will receive escalating doses of gocatamig until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig

  • Experimental
    Part 2 Arm 5: Gocatamig Monotherapy in China

    Participants in China will receive escalating doses of gocatamig until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig

  • Experimental
    Part 2 Arm 6: Gocatamig

    Participants will receive gocatamig at a determined dose until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig

  • Experimental
    Part 3 Arm 7: Gocatamig and Durvalumab

    Participants will receive gocatamig and durvalumab at a determined dose until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig · Biological: Durvalumab

  • Experimental
    Part 2 Arm 8: Gocatamig (Alternate Presentation)

    Participants will receive an alternate presentation of gocatamig at a determined dose until documented disease progression or discontinuation criteria are met.

    Biological: Gocatamig

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE in the study will be presented.

    Time frame: Up to approximately 44 months

  2. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)

    A DLT is defined as any drug-related adverse event (AE) observed during the DLT evaluation period that meet pre-defined DTL criteria. Toxicities will be graded using National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) version 5.0, or the American Society for Transplant and Cellular Therapy (ASTCT) criteria. The number of participants who experience at least one DLT will be presented.

    Time frame: Up to approximately 3 weeks

  3. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue the study intervention due to an AE in the study will be presented.

    Time frame: Up to approximately 44 months

  4. Part 1: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by the investigator will be presented.

    Time frame: Up to approximately 44 months

Secondary outcomes

  1. Part 1, Part 2 (Arm 5, Arm 6, and Arm 8), and Part 3 (Arm 7): Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by the investigator will be presented.

    Time frame: Up to approximately 44 months

  2. Part 1, Part 2 (Arm 6 and Arm 8), and Part 3 (Arm 7): Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented PD or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by the investigator will be presented.

    Time frame: Up to approximately 44 months

  3. Part 2 (Arm 5, Arm 6, and Arm 8) and Part 3 (Arm 7): ORR

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by the investigator will be presented.

    Time frame: Up to approximately 44 months

  4. Maximum Concentration (Cmax) of gocatamig

    Cmax is the maximum concentration of the study drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  5. Cmax of ifinatamab deruxtecan (I-DXd)

    Cmax is the maximum concentration of the study drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  6. Cmax of Anti-B7-H3 Antibody

    Cmax is the maximum concentration of the study drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  7. Cmax of Deruxtecan (DXd)

    Cmax is the maximum concentration of the study drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of the drug payload deruxtecan (DXd).

    Time frame: At designated timepoints (up to approximately 44 months)

  8. Cmax of Durvalumab

    Cmax is the maximum concentration of the study drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of durvalumab.

    Time frame: At designated timepoints (up to approximately 44 months)

  9. Time to maximum concentration (Tmax) of gocatamig

    Tmax is the amount of time that a drug is present at the maximum concentration is observed in plasma. Blood samples will be collected to determine the Tmax of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  10. Tmax of I-DXd

    Tmax is the amount of time that a drug is present at the maximum concentration is observed in plasma. Blood samples will be collected to determine the Tmax of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  11. Tmax of Anti-B7-H3 Antibody

    Tmax is the amount of time that the drug is present at the maximum concentration is observed in plasma. Blood samples will be collected to determine the Tmax of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  12. Tmax of DXd

    Tmax is the amount of time that the drug is present at the maximum concentration is observed in plasma. Blood samples will be collected to determine the Tmax of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  13. Area Under the Concentration-Time Curve Over the Dosing Interval t (AUCt) of gocatamig

    AUCt is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration. Blood samples will be collected to determine the AUCt of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  14. AUCt of I-DXd

    AUCt is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration. Blood samples will be collected to determine the AUCt of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  15. AUCt of Anti-B7-H3 Antibody

    AUCt is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration. Blood samples will be collected to determine the AUCt of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  16. AUCt of DXd

    AUCt is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration. Blood samples will be collected to determine the AUCt of the drug payload Dxd.

    Time frame: At designated timepoints (up to approximately 44 months)

  17. Terminal Half-Life (t1/2) of gocatamig

    t½ is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak. Blood samples will be collected to determine the t1/2 of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  18. t1/2 of I-DXd

    t½ is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak. Blood samples will be collected to determine the t1/2 of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  19. t1/2 of Anti-B7-H3 Antibody

    t½ is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak. Blood samples will be collected to determine the t1/2 of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  20. t1/2 of DXd

    t½ is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak. Blood samples will be collected to determine the t1/2 of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  21. Steady State Maximum Concentration (Cmax,ss) of gocatamig

    Cmax,ss is a measure of the maximum level of drug in the blood, measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Cmax,ss of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  22. Cmax,ss of I-DXd

    Cmax,ss is a measure of the maximum level of drug in the blood, measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Cmax,ss of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  23. Cmax,ss of Anti-B7-H3 Antibody

    Cmax,ss is a measure of the maximum level of drug in the blood, measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Cmax,ss of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  24. Cmax,ss of DXd

    Cmax,ss is a measure of the maximum level of drug in the blood, measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Cmax,ss of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  25. Cmax,ss of Durvalumab

    Cmax,ss is a measure of the maximum level of drug in the blood, measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Cmax,ss of the durvalumab.

    Time frame: At designated timepoints (up to approximately 44 months)

  26. Steady State Ctrough (Ctrough,ss) of gocatamig

    Ctrough,ss is defined as the trough concentration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Ctrough,ss of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  27. Ctrough,ss of I-DXd

    Ctrough,ss is defined as the trough concentration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Ctrough,ss of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  28. Ctrough,ss of Anti-B7-H3 Antibody

    Ctrough,ss is defined as the trough concentration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Ctrough,ss of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  29. Ctrough,ss of DXd

    Ctrough,ss is defined as the trough concentration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Ctrough,ss of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  30. Ctrough,ss of Durvalumab

    Ctrough,ss is defined as the trough concentration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Ctrough,ss of durvalumab.

    Time frame: At designated timepoints (up to approximately 44 months)

  31. Steady State Time to Maximum Concentration (Tmax,ss) of gocatamig

    Tmax,ss is the amount of time that a drug is present at the maximum concentration is observed in plasma measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Tmax,ss of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  32. Tmax,ss of I-DXd

    Tmax,ss is the amount of time that a drug is present at the maximum concentration is observed in plasma measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Tmax,ss of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  33. Tmax,ss of Anti-B7-H3 Antibody

    Tmax,ss is the amount of time that a drug is present at the maximum concentration is observed in plasma measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Tmax,ss of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  34. Tmax,ss of DXd

    Tmax,ss is the amount of time that a drug is present at the maximum concentration is observed in plasma measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the Tmax,ss of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  35. Area Under the Steady State Concentration-Time Curve Over Dosing Interval t (AUCt,ss) of gocatamig

    AUCt,ss is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the AUCt,ss of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  36. AUCt,ss of I-DXd

    AUCt,ss is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the AUCt,ss of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  37. AUCt,ss of Anti-B7-H3 Antibody

    AUCt,ss is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the AUCt,ss of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  38. AUCt,ss of DXd

    AUCt,ss is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after drug administration measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the AUCt,ss of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  39. Steady state t1/2 (t1/2,ss) of gocatamig

    t1/2,ss is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the t1/2,ss of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  40. t1/2,ss of I-DXd

    t1/2,ss is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the t1/2,ss of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  41. t1/2,ss of Anti-B7-H3 Antibody

    t1/2,ss is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the t1/2,ss of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  42. t1/2,ss of DXd

    t1/2,ss is defined as the time required for plasma drug concentration of study drug to decrease by 50% from peak measured at steady state (time at which the amount of drug eliminated by the body is in equilibrium with the amount taken in). Blood samples will be collected to determine the t1/2,ss of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  43. Accumulation Ratio (AC) of gocatamig

    Blood samples will be collected to determine the AC of the drug gocatamig.

    Time frame: At designated timepoints (up to approximately 44 months)

  44. AC of I-DXd

    Blood samples will be collected to determine the AC of the drug I-DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  45. AC of Anti-B7-H3 Antibody

    Blood samples will be collected to determine the AC of the anti-B7-H3 antibody.

    Time frame: At designated timepoints (up to approximately 44 months)

  46. AC of DXd

    Blood samples will be collected to determine the AC of the drug payload DXd.

    Time frame: At designated timepoints (up to approximately 44 months)

  47. Incidence of Anti-Drug Antibodies (ADAs) Against gocatamig

    Blood samples collected at designated timepoints will be used to determine the ADA response to gocatamig. The incidence of ADAs for gocatamig will be presented.

    Time frame: At designated timepoints (up to approximately 44 months)

  48. Incidence of ADAs Against I-DXd

    Blood samples collected at designated timepoints will be used to determine the ADA response to I-DXd. The incidence of ADAs for I-DXd will be presented.

    Time frame: At designated timepoints (up to approximately 44 months)

  49. Incidence of ADAs Against Durvalumab

    Blood samples collected at designated timepoints will be used to determine the ADA response to durvalumab. The incidence of ADAs for durvalumab will be presented.

    Time frame: At designated timepoints (up to approximately 44 months)

07

Study locations

44 of 48 sites recruiting
  • University of Colorado Anschutz Medical Campus ( Site 1110)
    Aurora, Colorado 80045, United States
    Recruiting
    • Study Coordinator · Contact303-724-6268
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)
    Miami, Florida 33136, United States
    Recruiting
    • Study Coordinator · Contact305-243-1754
  • University of Chicago ( Site 1108)
    Chicago, Illinois 60637, United States
    Recruiting
    • Study Coordinator · Contact773-702-6149
  • Dana Farber Cancer Institute ( Site 1105)
    Boston, Massachusetts 02215, United States
    Recruiting
    • Study Coordinator · Contact617-632-6049
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Study Coordinator · Contact551-996-5863
  • Roswell Park Cancer Institute ( Site 1107)
    Buffalo, New York 14263, United States
    Recruiting
    • Study Coordinator · Contact716-845-3167
  • Providence Portland Medical Center ( Site 1101)
    Portland, Oregon 97213, United States
    Recruiting
    • Study Coordinator · Contact503-215-5696
  • Sarah Cannon Research Institute ( Site 7001)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact844-482-4812
  • Medical College of Wisconsin ( Site 1112)
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Study Coordinator · Contact414-805-8900
  • Hospital Universitario Austral ( Site 2204)
    Pilar, Buenos Aires B1629WWA, Argentina
    Recruiting
    • Study Coordinator · Contact+5402304482000
  • Sanatorio Parque ( Site 2203)
    Rosario, Santa Fe Province S2000DSV, Argentina
    Recruiting
    • Study Coordinator · Contact+5493416955611
  • Princess Alexandra Hospital ( Site 5300)
    Woolloongabba, Queensland 4102, Australia
    Recruiting
    • Study Coordinator · Contact+61731766577
  • Monash Health ( Site 5301)
    Clayton, Victoria 3168, Australia
    Recruiting
    • Study Coordinator · Contact+61417607416
  • FALP ( Site 2100)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56224205098
  • Pontificia Universidad Catolica de Chile ( Site 2102)
    Santiago, Region M. de Santiago 8330032, Chile
    Recruiting
    • Study Coordinator · Contact+5690233407
  • Bradfordhill ( Site 2101)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • Beijing Cancer Hospital ( Site 5401)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact(010) 88121122
  • Fujian Cancer Hospital ( Site 5413)
    Fuzhou, Fujian 350014, China
    Recruiting
    • Study Coordinator · Contact0591-62002053
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403)
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Study Coordinator · Contact025-83106666
  • Shanghai Chest Hospital ( Site 5400)
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • Study Coordinator · Contact021-22200000
  • Shanghai Pulmonary Hospital ( Site 5405)
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Study Coordinator · Contact15801709047
  • West China Hospital of Sichuan University ( Site 5416)
    Chengdu, Sichuan 610041, China
    Recruiting
    • Study Coordinator · Contact02885423237
  • The First Affiliated Hospital, Zhejiang University ( Site 5404)
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Study Coordinator · Contact13675843246
  • Rambam Health Care Campus ( Site 3202)
    Haifa, 3109601, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shaare Zedek Medical Center ( Site 3200)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact026555768
  • Rabin Medical Center ( Site 3203)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239378101
  • Sheba Medical Center ( Site 3201)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact97235304498
  • Aichi Cancer Center ( Site 5000)
    Nagoya, Aichi-ken 464-8681, Japan
    Recruiting
    • Study Coordinator · Contact+81-52-762-6111
  • National Cancer Center Hospital East ( Site 5001)
    Kashiwa, Chiba 277-0882, Japan
    Recruiting
    • Study Coordinator · Contact+81-4-7133-1111
  • Kansai Medical University Hospital ( Site 5004)
    Hirakata, Osaka 573-1191, Japan
    Recruiting
    • Study Coordinator · Contact+81-72-804-2808
  • Cancer Institute Hospital of JFCR ( Site 5002)
    Koto, Tokyo 135-8550, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3520-0111
  • Seoul National University Hospital ( Site 5100)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact+82220723559
  • Severance Hospital, Yonsei University Health System ( Site 5102)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact+82215991004
  • Samsung Medical Center ( Site 5101)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234101795
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 3310)
    Eixample, Barcelona 08036, Spain
    Recruiting
    • Study Coordinator · Contact+34932275402
  • Institut Català d'Oncologia - L'Hospitalet ( Site 3317)
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
    Recruiting
    • Study Coordinator · Contact+34932607744
  • Hospital Clinico San Carlos... ( Site 3316)
    Madrid, Madrid, Comunidad de 28040, Spain
    Recruiting
    • Study Coordinator · Contact34913303000x484804
  • Hospital Universitari Vall d'Hebron ( Site 3311)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34934894158
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact+34915504800ext2805
  • Hospital Universitario HM Sanchinarro ( Site 3313)
    Madrid, 28050, Spain
    Recruiting
    • Study Coordinator · Contact+34917567984
  • Hospital Universitario Virgen de la Victoria ( Site 3312)
    Málaga, 29010, Spain
    Recruiting
    • Study Coordinator · Contact+34671594566
  • National Cheng Kung University Hospital ( Site 5202)
    Tainan, 704, Taiwan
    Recruiting
    • Study Coordinator · Contact+88662353535
  • Taipei Medical University Hospital ( Site 5201)
    Taipei, 11030, Taiwan
    Recruiting
    • Study Coordinator · Contact+886227372181
  • Hacettepe Universite Hastaneleri ( Site 3410)
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903123055000
  • Ankara Bilkent Sehir Hastanesi ( Site 3412)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90312 552 6084
  • National Institute for Health Research UCLH Clinical Research Facility ( Site 3902)
    London, London, City of W1T 7HA, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Clatterbridge Cancer Centre ( Site 3903)
    Liverpool, L7 8YA, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Christie NHS Foundation Trust ( Site 3901)
    Manchester, M20 4BX, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2029, 47 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 47 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Apr 2029 → Feb 2029 and completion Apr 2029 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Feb 15, 2029was Apr 2029
CompletionEst.
Feb 15, 2029was Apr 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 27, 2029→Feb 15, 2029
Oct 6, 2026
Study completion
Apr 27, 2029→Feb 15, 2029
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Apr 27, 2029→Feb 15, 2029
    Study completion Apr 27, 2029→Feb 15, 2029

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06780137
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Feb 27, 2025
Primary completion
Feb 15, 2029 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gocatamig · Ifinatamab deruxtecan

Start the discussion